This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Abraxane
  • /
  • A Study of Atezolizumab in Combination With Carbop...
Clinical trial

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower130)

Read time: 3 mins
Last updated:29th Apr 2015
Identifier: NCT02367781

This randomized Phase III, multicenter, open-label study is designed to evaluate the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin+nab-paclitaxel compared with treatment with carboplatin+nab-paclitaxel in chemotherapy-naive participants with Stage IV non-squamous NSCLC. Participants will be randomized in a 2:1 ratio to Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) or Arm B (Nab-Paclitaxel+Carboplatin).

Study Type: Interventional  (Clinical Trial)
Actual Enrollment : 724 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Nab-Paclitaxel for Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer
Actual Study Start Date: April 30, 2015
Actual Primary Completion Date: March 15, 2018
Estimated Study Completion Date: December 28, 2019

- Experimental:
Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)
- Active Comparator: Arm B (Nab-Paclitaxel+Carboplatin)

Category Value
Date last updated at source 2018-06-13
Study type(s) Interventional
Expected enrolment 724
Study start date 2015-04-30
Estimated primary completion date 2018-03-15

View full details